Today: 20 May 2026
Browse Category

NYSE:REP 3 November 2025 - 13 April 2026

Trump Orders Iran Blockade as Oil Nears $150 in Europe and Stocks Slip

Trump Orders Iran Blockade as Oil Nears $150 in Europe and Stocks Slip

Europe’s immediate-delivery crude surged to nearly $150 a barrel and U.S. stock futures dropped after the U.S. ordered a blockade on Iranian port traffic, set to begin at 1400 GMT. North Sea Forties crude hit a record $148.87, while Brent rose above $100. Shipping through the Gulf showed disruption, with tankers rerouting and Tehran warning of retaliation. Dow, S&P 500, and Nasdaq futures all fell before the open.
13 April 2026
·
Crude oil price today: Brent, WTI rebound after 4% drop as Iran strike fears ease

Crude oil price today: Brent, WTI rebound after 4% drop as Iran strike fears ease

Brent crude rose 50 cents to $64.26 a barrel by 1000 GMT Friday, rebounding after a sharp drop tied to easing fears of U.S. strikes on Iran. U.S. crude inventories climbed by 3.4 million barrels last week, while gasoline stocks jumped 9 million barrels, EIA data showed. Repsol, ENI, and Maurel & Prom are seeking U.S. approval to resume Venezuelan crude exports. OPEC projected 2027 oil demand growth at 1.34 million barrels per day.
16 January 2026
·····
Oil Prices Rollercoaster: Trade War Fears & OPEC Moves Spark 5-Month Lows

Oil Price Rebound as OPEC Freezes Output Hikes: Winners, Losers, and 2026 Outlook

OPEC+ will limit its oil supply increase to 137,000 barrels per day in December and pause further hikes through early 2026, citing weak demand and glut fears. Brent crude rebounded to $65 after the announcement, lifting oil stocks like BP and Shell. Analysts expect stable prices in the near term, but forecasts for 2026 remain split, with estimates ranging from $52 to $60 per barrel.
3 November 2025
·····

Stock Market Today

  • Tesla Q1 2026 Earnings Beat; Stock Faces Mixed Outlook for 2030
    May 20, 2026, 10:24 AM EDT. Tesla (TSLA) reported Q1 2026 earnings per share (EPS) of $0.41, exceeding the $0.36 consensus, with automotive gross margin rising to 21.1% from 16.2%. Operating income increased 135.8% year-on-year (YoY), and services plus Full Self-Driving (FSD) revenue jumped 42% to $3.75 billion, with 1.28 million active FSD subscriptions up 51%. Despite strong fundamentals, Tesla shares fell 8.83% year-to-date to $409.99 amid skepticism about AI monetization and scaling autonomy. Wall Street's average target is about $412, while a proprietary model estimates a base case price of $510 by 2030, with a bull case of $645. Achieving $650 requires significant price-to-earnings multiple expansion or sharp EPS growth from AI ventures, amid challenges like increased operating expenses and production constraints.

Latest articles

POET Technologies Jumps After $400M AI Photonics Raise, Dilution Questions Linger

POET Technologies Jumps After $400M AI Photonics Raise, Dilution Questions Linger

20 May 2026
POET Technologies shares rose 11% to $14.55 in early Nasdaq trading Wednesday after closing a US$400 million direct offering of 19 million shares and warrants. The rebound followed an 8% drop Tuesday on dilution concerns. The company reported Q1 revenue of $503,389 and a net loss of $12.3 million. A recent $50 million order from Lumilens could scale to $500 million over five years if production ramps up.
Nokia’s U.S. Broadband Order Arrives While AI-Driven Gains Test Supply Chain

Nokia’s U.S. Broadband Order Arrives While AI-Driven Gains Test Supply Chain

20 May 2026
Nokia shares rose 3.37% in Helsinki trading Wednesday after the FCC conditionally approved its Beacons and ONT devices, exempting them from U.S. Covered List restrictions. Nokia also transferred 975,289 treasury shares to equity plan participants. Dell’Oro Group forecasts the optical transport equipment market will grow 16% in 2026, driven by AI data centers.
Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left

Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left

20 May 2026
Biogen completed its acquisition of Apellis Pharmaceuticals, removing APLS shares from Nasdaq and paying investors $41 per share plus a contingent value right tied to Syfovre sales. Apellis shareholders tendered 82.4% of outstanding stock before the offer expired May 13. Biogen shares rose 0.9% to $192.34 Wednesday. The CVR could pay up to $4 if Syfovre meets future sales targets.
Go toTop